THE EFFECT OF HAART ON HCV REPLICATION AND IMMUNE RESPONSE TO HCV

HAART 对 HCV 复制和 HCV 免疫反应的影响

• 批准号: 7379318
• 负责人: MARGARET C SHUHART
• 金额: $ 0.23万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379318
• 关键词: EFFECT; HAART; HCV; REPLICATION; IMMUNE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HCV-infected individuals who are co-infected with HIV have a significantly increased risk of cirrhosis and liver failure when compared to those who are HIV-negative. Furthermore, severe HIV-related immunodeficiency appears to be an independent predictor of advanced liver disease. Many HIV-infected individuals are now treated with highly active antiretroviral therapy (HAART), and more than 50% experience immune reconstitution with therapy. We will collect blood and perform liver biopsies in co-infected patients before and 12 months after initiating HAART. Assays measuring HCV replication and the HCV-specific immune response will allow us to test several hypotheses regarding the effect of HAART-related immune reconstitution on hepatitis C replication, immune responses, and HCV liver disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。与HIV阴性者相比，HCV感染者合并HIV感染者发生肝硬化和肝功能衰竭的风险显著增加。此外，严重的HIV相关免疫缺陷似乎是晚期肝病的独立预测因子。许多艾滋病毒感染者现在接受高效抗逆转录病毒疗法（HAART）治疗，超过50%的人在治疗后经历了免疫重建。我们将在开始HAART治疗前和治疗后12个月对合并感染的患者进行血液采集和肝脏活检。测定HCV复制和HCV特异性免疫应答的试验将使我们能够检验关于HAART相关免疫重建对丙型肝炎复制、免疫应答和HCV肝病的影响的几种假设。